TRIAPEX LABORATORIES CO., LTD.

江苏鼎泰药物研究(集团)股份有限公司

Contract research organization providing nonclinical safety, efficacy and DMPK studies and integrated clinical trial services to pharmaceutical companies and research institutions worldwide, with focus on cardiometabolic, CNS, ophthalmology, autoimmune and oncology diseases. No. 1 CRO in China for nonclinical cardiometabolic studies in 2025, per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Single product, business line or region
• Raw material and commodity prices
• Backlog and project economics
• Capacity and utilisation
• Losses and path to profitability
• Decline in revenue or profit
• Net current liabilities or net liabilities
• Negative operating cash flow
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Non-IFRS measures and adjustments
• Related-party transactions and balances